Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Angewandte Chemie (International Ed. in English)|May 10, 2022
Selective Stepwise Arylation of Unprotected Peptides by PtIV ComplexesXiaoxi Lin, Elvira Haimov, Boris Redko, et al.Biopolymers|December 15, 2015
Biolabile peptidyl delivery systems toward sequential drug releaseElena Ragozin, Boris Redko, Elena Tuchinsky, et al.Medicinal Chemistry (Shariqah (United Arab Emirates))|December 20, 2014
Antiproliferative Effect of Novel Aminoacridine-based CompoundsAnna Munder, Yoni Moskovitz, Boris Redko, et al.European Journal of Medicinal Chemistry|August 2, 2014
"Switch off/switch on" regulation of drug cytotoxicity by conjugation to a cell targeting peptideYossi Gilad, Michael A Firer, Alex Rozovsky, et al.Oncotarget|October 22, 2016
Toward the development of a novel non-RGD cyclic peptide drug conjugate for treatment of human metastatic melanomaBoris Redko, Helena Tuchinsky, Tamar Segal, et al.Biopolymers|June 11, 2015
Synthesis, drug release, and biological evaluation of new anticancer drug-bioconjugates containing somatostatin backbone cyclic analog as a targeting moietyBoris Redko, Elena Ragozin, Bazylevich Andreii, et al.International Journal of Molecular Sciences|September 10, 2021
Anti-Cancer Effects of Cyclic Peptide ALOS4 in a Human Melanoma Mouse ModelBar Levi, Shiri Yacobovich, Michael Kirby, et al.Science Advances|May 18, 2022
Structural basis for long-chain isoprenoid synthesis by cis-prenyltransferasesMoshe Giladi, Michal Lisnyansky Bar-El, Pavla Vaňková, et al.Oncotarget|August 25, 2016
Novel synthetic cyclic integrin αvβ3 binding peptide ALOS4: Antitumor activity in mouse melanoma modelsShiri Yacobovich, Lena Tuchinsky, Michael Kirby, et al.Proceedings of the National Academy of Sciences of the United States of America|August 15, 2022
Allosteric inhibitors targeting the calmodulin-PIP2 interface of SK4 K+ channels for atrial fibrillation treatmentShira Burg, Shir Shapiro, Asher Peretz, et al.Pageof 2